Business Development (9)

Challenge: A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested...

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...

Challenge: A pharmaceutical company with marketed therapeutics in several respiratory disorders wanted to supplement its internal pipeline with external innovation. The company had already searched...

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target. Alacrita...

Challenge: A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.